| Not Yet Recruiting | Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian Can NCT07286162 | University Health Network, Toronto | Phase 3 |
| Not Yet Recruiting | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer NCT07454018 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors NCT06769425 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Sing NCT07495384 | The First Hospital of Jilin University | N/A |
| Recruiting | An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian NCT06560112 | Akeso | Phase 2 |
| Not Yet Recruiting | Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients NCT06070285 | Power Life Sciences Inc. | — |
| Recruiting | Combination Therapy for Recurrent Ovarian Cancer NCT05610735 | Sham Sunder Kakar | Phase 1 / Phase 2 |
| Recruiting | A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Partic NCT06365853 | AbbVie | Phase 2 |
| Active Not Recruiting | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer NCT06107868 | University Health Network, Toronto | Phase 1 |
| Unknown | A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Ca NCT06308406 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer NCT05942300 | Lan Coffman | Phase 1 |
| Terminated | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors NCT06257758 | Valerio Therapeutics | Phase 1 / Phase 2 |
| Withdrawn | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi NCT05126342 | AGO Research GmbH | Phase 2 |
| Unknown | The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab NCT05819060 | Fudan University | Phase 2 |
| Recruiting | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER NCT03458221 | Gynaecologisch Oncologisch Centrum Zuid | Phase 2 / Phase 3 |
| Unknown | Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer NCT05270720 | West China Second University Hospital | Phase 1 |
| Active Not Recruiting | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive R NCT05335993 | CanariaBio Inc. | Phase 2 |
| Unknown | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer NCT05311579 | Lei Li | Phase 2 |
| Completed | A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer NCT04718740 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer NCT04457089 | Marc Goodman | EARLY_Phase 1 |
| Completed | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovaria NCT03776812 | Corcept Therapeutics | Phase 2 |
| Withdrawn | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian C NCT03632798 | Cordgenics, LLC | Phase 3 |
| Recruiting | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Rec NCT03564340 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer NCT03430518 | Amy Tiersten | Phase 1 |
| Unknown | Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer NCT03618706 | Yonsei University | Phase 2 |
| Completed | Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer NCT02849353 | Fuda Cancer Hospital, Guangzhou | Phase 1 / Phase 2 |
| Completed | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer NCT02788708 | Floor Backes | Phase 1 |
| Completed | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer NCT02737787 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Withdrawn | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer NCT02117817 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer NCT02303912 | Imperial College Healthcare NHS Trust | Phase 1 |
| Completed | Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer NCT02195973 | University of Alabama at Birmingham | Phase 1 |
| Withdrawn | LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma NCT02083536 | University of Miami | Phase 1 |
| Completed | H.O.P.E: Helping Ovarian Cancer Patients Cope NCT02090582 | Duke University | N/A |
| Terminated | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment NCT02035345 | Massachusetts General Hospital | Phase 4 |
| Unknown | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer NCT01802749 | National Cancer Institute, Naples | Phase 3 |
| Completed | An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovari NCT01869400 | PharmaMar, Spain | — |
| Unknown | A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Plat NCT01851746 | Wuhan University | — |
| Completed | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer NCT01809379 | Ruhr University of Bochum | Phase 2 |
| Completed | Interactive Educational Website for Women With Ovarian Cancer & Caregivers NCT01626014 | University of Minnesota | EARLY_Phase 1 |
| Terminated | A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy NCT01659554 | Columbia University | Phase 2 |
| Completed | Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian NCT01639885 | Leiden University Medical Center | Phase 1 / Phase 2 |
| Completed | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma NCT01381861 | Tracon Pharmaceuticals Inc. | Phase 2 |
| Completed | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R NCT01637532 | Leiden University Medical Center | Phase 1 / Phase 2 |
| Approved For Marketing | Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer NCT03025867 | Tesaro, Inc. | — |